ESMO study shows microbiome potential for CRC detection

By staff writers

September 12, 2022 -- Universal Diagnostics on Monday announced the results of a proof-of-principle study demonstrating that the analysis of microbiome signatures in plasma can assist in the early detection of colorectal cancer (CRC).

The company presented the findings on Sunday at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris.

According to Universal, the study concluded that changes in gut microbiota are linked to CRC development and progression. The study also found that measuring cancer-related microbiome alterations in plasma cell-free DNA (cfDNA) could offer an accurate, noninvasive approach for early cancer detection, leading to decreased cancer mortality. And the study revealed that cfDNA analysis coupled with model building achieved high sensitivity, including at stages I/II and III/IV, and equally accurate specificity.

The announcement follows the reporting of earlier findings by the firm associated with early-stage CRC detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation, mutation, and fragmentation patterns by using targeted sequencing analysis, advanced computational biology, and machine learning algorithms to detect CRC and advanced adenomas.

"While methylation, mutation and fragmentation are still the core of early CRC detection, we think microbiome is an interesting addition to our proprietary technological platform Signal-X as we build out the platform," Christian Hense, COO at Universal DX, said in a statement.

Predicine to present posters on liquid biopsy tech at ESMO
Predicine said on Thursday that it will present four posters at the European Society of Medical Oncology (ESMO) annual meeting in Paris.
Illumina to present oncology research abstracts at ESMO 2022
Illumina this week announced the upcoming presentation of multiple oncology research abstracts at this year's European Society of Medical Oncology (ESMO)...
Foundation to present on genomic profiling at ESMO 2022
Foundation Medicine said it will present 14 abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress that show how genomic profiling...
cfDNA detection may simplify breast cancer monitoring: study
University of Colorado researchers have developed a blood-based cell-free DNA method that they believe could solve a challenge in monitoring breast cancer...
Universal Diagnostics touts blood-based lung cancer test
Universal Diagnostics announced results of its investigational blood-based lung cancer test, which showed that it can detect different lung cancer subtypes...

Copyright © 2022

Last Updated lo 9/12/2022 1:17:54 PM